Purizumubaiorabo

206A.TTSE GROWTHPharmaceutical

Filed as PRISM BioLab Co.,LTD (2024-12–2026-05)

Key numbers · FY ended 2025-09

Revenue¥677m+121.6% YoY Operating income−¥774m—Total assets¥3.1bn-31.9% YoY EPS (basic)¥-22.82+31.9% YoY

Full financial history and reports →

Stock price206A · View chart ↗

Open the price chart on TradingView.

Latest filings

Thu, Aug 6 · JST1 filing

16:255% STAKEPurizumubaiorabo · SBI SECURITIES Co., Ltd. · 5.50% → 0.39%−5.11pp

Mon, Dec 8 · JST3 filings

16:515% STAKEPurizumubaiorabo · DBJ Capital Co., Ltd. · 16.49% → 15.24%−1.25pp 16:105% STAKEPurizumubaiorabo · WM PARTNERS Co., Ltd. · 6.63% → 4.88%−1.75pp 16:055% STAKEPurizumubaiorabo · WM PARTNERS Co., Ltd. · 11.22% → 6.63%−4.59pp

Tue, Jul 29 · JST1 filing

09:15MATERIALPrism BioLab · Event with a material impact on financial position

All filings →

Major holders (5%+) · 5

Holder	Stake	Change	Filed
DBJ Capital Co., Ltd.	15.24%	-1.25pp	2025-12-08
DCI Partners Co., Ltd.	10.12%	-1.05pp	2024-10-18
Eli Lilly and Company	7.07%	—	2024-07-04
Dai Takehara	6.08%	-0.09pp	2024-07-08
nakajima kiichiro	5.29%	—	2024-07-05

Each holder's own ratio from its most recent large-shareholding report.